Payment overview · 2025
General Payments
$1,139.26
62 reported records · 18 companies
Healthcare provider profile · identity verified
Mohammad Ahmed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHESTERFIELD, MO · NPI 1386636447
Verified facts
What the public records show
CMS Open Payments records show Mohammad Ahmed, MD received $1,139.26 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $206.46 | 18.1% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $178.71 | 15.7% | 21 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.35 | 13.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.18 | 10.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.64 | 7.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.72 | 4.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.18 | 4.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.36 | 3.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.00 | 3.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.70 | 3.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.56 | 2.8% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $27.48 | 2.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $23.84 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.72 | 2.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.24 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.24 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,139.26 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $166.92 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.64 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.29 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $122.18 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.18 | 5 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $110.41 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $101.93 | 16 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $58.95 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.36 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $11.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 33 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 177 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 151 |
| Alprazolam | Alprazolam | 440 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 126 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 51 |
| Lisinopril | Lisinopril | 292 | 82 |
| Losartan Potassium | Losartan Potassium | 286 | 78 |
| Metformin Hcl | Metformin Hcl | 277 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 83 |
| Gabapentin | Gabapentin | 246 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 67 |
| Potassium Chloride | Potassium Chloride | 219 | 65 |
| Furosemide | Furosemide | 198 | 59 |
| Omeprazole | Omeprazole | 197 | 55 |
| Tramadol Hcl | Tramadol Hcl | 196 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 50 |
| Eliquis | Apixaban | 177 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 45 |
| Allopurinol | Allopurinol | 161 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 43 |
| Simvastatin | Simvastatin | 147 | 42 |
| Sertraline Hcl | Sertraline Hcl | 146 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 38 |
| Cefuroxime | Cefuroxime Axetil | 120 | 95 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 15 |
| Trazodone Hcl | Trazodone Hcl | 114 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 55 |
| Irbesartan | Irbesartan | 111 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 104 | 33 |
| Famotidine | Famotidine | 103 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 31 |
| Prednisone | Prednisone | 99 | 73 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 31 |
| Carvedilol | Carvedilol | 93 | 29 |
| Glimepiride | Glimepiride | 90 | 29 |
| Azithromycin | Azithromycin | 89 | 75 |
| Celecoxib | Celecoxib | 88 | 19 |
| Januvia | Sitagliptin Phosphate | 87 | 21 |
| Atenolol | Atenolol | 82 | 21 |
| Lorazepam | Lorazepam | 73 | 19 |
| Donepezil Hcl | Donepezil Hcl | 69 | 18 |
| Ezetimibe | Ezetimibe | 68 | 20 |
| Montelukast Sodium | Montelukast Sodium | 65 | 21 |
| Bumetanide | Bumetanide | 64 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 22 |
| Warfarin Sodium | Warfarin Sodium | 62 | 13 |
| Azelastine Hcl | Azelastine Hcl | 61 | 15 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 11 |
| Clonazepam | Clonazepam | 56 | 19 |
| Diazepam | Diazepam | 56 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 33 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 52 | 22 |
| Spironolactone | Spironolactone | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 43 |
| Methocarbamol | Methocarbamol | 49 | 24 |
| Valacyclovir | Valacyclovir Hcl | 49 | 13 |
| Ozempic | Semaglutide | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Meloxicam | Meloxicam | 46 | 16 |
| Buspirone Hcl | Buspirone Hcl | 45 | 15 |
| Fenofibrate | Fenofibrate | 44 | 11 |
| Methylprednisolone | Methylprednisolone | 44 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Finasteride | Finasteride | 33 | 11 |
| Creon | Lipase/Protease/Amylase | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 15 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 16 |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Clotrimazole | Clotrimazole | 21 | 11 |
| Colchicine | Colchicine | 21 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 16 |
| Fluconazole | Fluconazole | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,139.26 · 62 records | ABBVIE INC. | AIRSUPRA, AMPLATZER AMULET, AREXVY, Bimzelx, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, INCEPTIV, JARDIANCE, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SAPHNELO, SHINGRIX, TREMFYA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XELJANZ, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error